09.07.2012 - Spanish molecular diagnostics company Inbiomotion S.L. has raised €2m in a series A round.
The new investor, Ysios Capital, led the round. Fundacio Vila Casas and JVRisk Technologies also participated. Inbiomotion is a 2010 spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Catalan Institution for Research and Advanced Studies (ICREA). The firm develops biomarkers to predict bone metastasis from primary tumour biopsies, with its lead biomarker coding for an undisclosed nuclear protein. Inbiomotion, based in the Barcelona Science Park and founded by Roger Gomis, is carrying out a trial to validate the capacity of its marker to predict future bone metastasis using technology developed by IRB Barcelona. The investment raised will go to fund the validation of this marker through various clinical trials in Barcelona and England, and to advance development through regulatory approval. According to Inbiomotion, its biomarker has been validated with more than 900 patient samples in two different trials carried out with independent techniques (gene expression and immunohistochemistry), with a negative predictive value of 95%.
31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.
31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.
24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.
23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.
17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.
12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.